Stereotaxis (STXS) Stock Price, News & Analysis

Company Overview

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

Key Stats

• Today's Range: $1.96 to $2.05
• 50-Day Range: $1.60 to $2.29
• 52-Week Range: $1.54 to $2.72
• Volume: 238,282 shs
• Average Volume: 369,265 shs
• Market Capitalization: $171.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

STXS Stock Analysis - Frequently Asked Questions

How have STXS shares performed this year?

Stereotaxis' stock was trading at $2.29 on January 1st, 2025. Since then, STXS shares have decreased by 11.8% and is now trading at $2.02.
View the best growth stocks for 2025 here.

How were Stereotaxis' earnings last quarter?

Stereotaxis, Inc. (NYSEAMERICAN:STXS) issued its quarterly earnings results on Monday, November, 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. The company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $6.80 million. Stereotaxis had a negative net margin of 85.79% and a negative trailing twelve-month return on equity of 162.54%.
Read the conference call transcript.

Who are Stereotaxis' major shareholders?

Top institutional investors of Stereotaxis include Wealth Effects LLC (0.09%) and Cherry Creek Investment Advisors Inc. (0.05%).
View institutional ownership trends.

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Stereotaxis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/11/2024
• Today: 5/01/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:STXS
• CIK: 1289340
• Web: www.stereotaxis.com
• Phone: (314) 678-6100
• Fax: 314-678-6159
• Employees: 130
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,710,000.00
• Net Margins: -85.79%
• Pretax Margin: -85.79%
• Return on Equity: -162.54%
• Return on Assets: -51.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.39
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $26.77 million
• Price / Sales: 6.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 10.13

Miscellaneous

• Outstanding Shares: 84,730,000
• Free Float: 69,038,000
• Market Cap: $171.58 million
• Optionable: Not Optionable
• Beta: 1.54